KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Invested Capital (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Invested Capital readings, the most recent being -$204.7 million for Q4 2025.

  • On a quarterly basis, Invested Capital rose 29.91% to -$204.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$204.7 million, a 29.91% increase, with the full-year FY2025 number at -$204.7 million, up 29.91% from a year prior.
  • Invested Capital hit -$204.7 million in Q4 2025 for Esperion Therapeutics, down from -$137.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of -$137.5 million in Q3 2025 to a low of -$410.0 million in Q3 2023.
  • Median Invested Capital over the past 5 years was -$299.3 million (2021), compared with a mean of -$299.5 million.
  • Biggest five-year swings in Invested Capital: plummeted 4148.05% in 2021 and later surged 62.87% in 2025.
  • Esperion Therapeutics' Invested Capital stood at -$196.9 million in 2021, then crashed by 64.4% to -$323.8 million in 2022, then skyrocketed by 40.27% to -$193.4 million in 2023, then tumbled by 51.0% to -$292.0 million in 2024, then rose by 29.91% to -$204.7 million in 2025.
  • The last three reported values for Invested Capital were -$204.7 million (Q4 2025), -$137.5 million (Q3 2025), and -$378.7 million (Q2 2025) per Business Quant data.